MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma

Figures & data

Figure 1. mRNA expression levels of MAGE-A3 in DLBCL stages. (A) Expression of MAGE-A3 in DLBCL. Lane 1, 100-bp ladder; lane 2, testicular tissue; lane 3, PBLs from a healthy donor; lanes 4–11, DLBCL representative samples. (B) Real-time RT-PCR. The expression results were obtained from eight samples from stage II DLBCL patients; nine from stage III and eight from stage IV. Significant differences between results (P<0·05) were obtained by means of parametric test. T, testicular tissue.

Table 1. Association between clinical characteristics and MAGE-A3 expression in DLBCL patients

		MAGE-A3
Characteristics		Positive n (%)	Negative n (%)	P value
All patients (n = 28)		11 (39·3)	17 (60·7)
Age at diagnosis (year)	Median	37	51
	Range	19–69	18–65
	Over 60 years old	3 (27·3)	3 (17·6)
Sex	Male	5 (45·5)	8 (47·1)
	Female	6 (54·5)	9 (52·9)
Performance status greater than 2		0 (0)	0 (0)
Serum LDH level >normal		8 (72·7)	5 (29·4)	0·025*
More than 1 extranodal site		4 (36·4)	3 (17·6)
Stage III/IV		10 (90·9)	7 (41·2)	0·008*
IPI	Low	1 (9·1)	7 (41·2)	0·004*
	Low–intermediate	1 (9·1)	7 (41·2)
	High–intermediate	0 (0)	0 (0)
	High	9 (81·8)	3 (17·6)

Note: LDH: lactate dehydrogenase.

*Fisher’s exact test.

Figure 2. Protein expression of MAGE-A3/A6 in DLBCL stages. (A) MAGE-A3/A6 protein expression in DLBCL. Lane 1, PBLs from a healthy donor; lane 2, testicular tissue; lanes 3–11, DLBCL representative samples. (B) Densitometric semiquantification of the protein bands.

Figure 3. Survival according to MAGE-A3 expression in DLBCL. Overall survival in 11 patients with MAGE-A3 (+) and 17 patients with MAGE-A3 (−) DLBCL (P< 0·001).